help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kask, A.
Right arrow Articles by Schiöth, H. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kask, A.
Right arrow Articles by Schiöth, H. B.
Endocrinology Vol. 139, No. 12 5006-5014
Copyright © 1998 by The Endocrine Society

ARTICLES

Discovery of a Novel Superpotent and Selective Melanocortin-4 Receptor Antagonist (HS024): Evaluation in Vitro and in Vivo1

Ants Kask, Felikss Mutulis, Ruta Muceniece, Rein Pähkla, Ilze Mutule, Jarl E. S. Wikberg, Lembit Rägo and Helgi B. Schiöth

Department of Pharmacology, University of Tartu (A.K., R.P., L.R.), Ulikooli 18, 50090 Tartu, Estonia; the Department of Medicinal Chemistry (F.M., I.M.) and the Laboratory of Pharmacology (R.M.), Institute of Organic Synthesis, Aizkraukles 21, LV-1006, Riga, Latvia; and the Department of Pharmaceutical Pharmacology, Uppsala University (F.M., R.M., I.M., J.E.S.W., H.B.S.), 751 24 Uppsala, Sweden

Address all correspondence and requests for reprints to: Dr. Helgi B. Schiöth, Department of Pharmaceutical Pharmacology, Biomedical Center, Box 591, 751 24 Uppsala, Sweden. E-mail: helgis{at}bmc.uu.se

Several novel cyclic MSH analogs were synthesized, and their binding properties were tested on cells transiently expressing the human melanocortin-1 (MC1), MC3, MC4, and MC5 receptors. We discovered a novel substance (HS024) that showed about 20-fold selectivity and very high affinity (Ki = 0.29 nM) for the MC4 receptor. HS024 (cyclic [AcCys3,Nle4,Arg5,D-Nal7,Cys-NH211]{alpha}-MSH-(3–11)) has a 29-membered atom ring structure that includes an Arg in position 5. HS024 was found to antagonize an {alpha}MSH-induced cAMP response in cells expressing the human MC1, MC3, MC4, and MC5 receptor DNAs. HS024 also caused a dose-dependent increase in food intake, with a maximum response (4-fold increase) at a 1-nmol dose injected intracerebroventricularly in free feeding rats. We also tested SHU9119, a previously described nonselective MC receptor antagonist, and found HS024 and SHU9119 to have similar potencies for increasing food intake, although SHU9119 appeared to induce more serious side-effects. HS024 increased the food intake of free feeding rats to levels comparable to those in food-deprived rats, indicating that blockade of the MC4 receptor is a highly effective way to increase feeding. Moreover, we tested the effects of intracerebroventricular injections of HS024 in elevated plus-maze and open-field experiments on rats. In these tests, HS024 did not appear to affect emotionality or locomotor activity, suggesting that the MC4 receptor does not mediate the anxiogenic-like and locomotor effects related to the melanocortic peptides.




This article has been cited by other articles:


Home page
 EndocrinologyHome page
D. D. Lam, M. J. Przydzial, S. H. Ridley, G. S. H. Yeo, J. J. Rochford, S. O'Rahilly, and L. K. Heisler
Serotonin 5-HT2C Receptor Agonist Promotes Hypophagia via Downstream Activation of Melanocortin 4 Receptors
Endocrinology, March 1, 2008; 149(3): 1323 - 1328.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
S. C Harmer, D. J Pepper, K. Cooke, H. P J Bennett, and A. B Bicknell
Evidence of a possible role for Lys-{gamma}3-MSH in the regulation of adipocyte function
J. Endocrinol., January 1, 2008; 196(1): 149 - 158.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
C. Caruso, D. Durand, H. B. Schioth, R. Rey, A. Seilicovich, and M. Lasaga
Activation of Melanocortin 4 Receptors Reduces the Inflammatory Response and Prevents Apoptosis Induced by Lipopolysaccharide and Interferon-{gamma} in Astrocytes
Endocrinology, October 1, 2007; 148(10): 4918 - 4926.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
M. Lopez, C. J. Lelliott, S. Tovar, W. Kimber, R. Gallego, S. Virtue, M. Blount, M. J. Vazquez, N. Finer, T. J. Powles, et al.
Tamoxifen-Induced Anorexia Is Associated With Fatty Acid Synthase Inhibition in the Ventromedial Nucleus of the Hypothalamus and Accumulation of Malonyl-CoA.
Diabetes, May 1, 2006; 55(5): 1327 - 1336.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
D. Giuliani, C. Mioni, D. Altavilla, S. Leone, C. Bazzani, L. Minutoli, A. Bitto, M.-M. Cainazzo, H. Marini, D. Zaffe, et al.
Both Early and Delayed Treatment with Melanocortin 4 Receptor-Stimulating Melanocortins Produces Neuroprotection in Cerebral Ischemia
Endocrinology, March 1, 2006; 147(3): 1126 - 1135.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
T. C. Kent, K. S. J. Thompson, and L. H. Naylor
Development of a Generic Dual-Reporter Gene Assay for Screening G-Protein-Coupled Receptors
J Biomol Screen, August 1, 2005; 10(5): 437 - 446.
[Abstract] [PDF]

Home page
 J AndrolHome page
F. Giuliano
Control of Penile Erection by the Melanocortinergic System: Experimental Evidences and Therapeutic Perspectives
J Androl, September 1, 2004; 25(5): 683 - 691.
[Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
A. Catania, S. Gatti, G. Colombo, and J. M. Lipton
Targeting Melanocortin Receptors as a Novel Strategy to Control Inflammation
Pharmacol. Rev., March 1, 2004; 56(1): 1 - 29.
[Abstract] [Full Text] [PDF]

Home page
 Mol Biol EvolHome page
J. Klovins, T. Haitina, D. Fridmanis, Z. Kilianova, I. Kapa, R. Fredriksson, N. Gallo-Payet, and H. B. Schioth
The Melanocortin System in Fugu: Determination of POMC/AGRP/MCR Gene Repertoire and Synteny, As Well As Pharmacology and Anatomical Distribution of the MCRs
Mol. Biol. Evol., March 1, 2004; 21(3): 563 - 579.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. C. Lagerstrom, J. Klovins, R. Fredriksson, D. Fridmanis, T. Haitina, M. K. Ling, M. M. Berglund, and H. B. Schioth
High Affinity Agonistic Metal Ion Binding Sites within the Melanocortin 4 Receptor Illustrate Conformational Change of Transmembrane Region 3
J. Biol. Chem., December 19, 2003; 278(51): 51521 - 51526.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. Robas, E. Mead, and M. Fidock
MrgX2 Is a High Potency Cortistatin Receptor Expressed in Dorsal Root Ganglion
J. Biol. Chem., November 7, 2003; 278(45): 44400 - 44404.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J. M. Cerda-Reverter, A. Ringholm, H. B. Schioth, and R. E. Peter
Molecular Cloning, Pharmacological Characterization, and Brain Mapping of the Melanocortin 4 Receptor in the Goldfish: Involvement in the Control of Food Intake
Endocrinology, June 1, 2003; 144(6): 2336 - 2349.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. Chaki, S. Hirota, T. Funakoshi, Y. Suzuki, S. Suetake, T. Okubo, T. Ishii, A. Nakazato, and S. Okuyama
Anxiolytic-Like and Antidepressant-Like Activities of MCL0129 (1-[(S)-2-(4-Fluorophenyl)-2-(4-isopropylpiperadin-1-yl)ethyl]-4-[4-(2-methoxynaphthalen-1-yl)butyl]piperazine), a Novel and Potent Nonpeptide Antagonist of the Melanocortin-4 Receptor
J. Pharmacol. Exp. Ther., February 1, 2003; 304(2): 818 - 826.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
L. J. Seal, C. J. Small, W. S. Dhillo, S. A. Stanley, C. R. Abbott, M. A. Ghatei, and S. R. Bloom
PRL-Releasing Peptide Inhibits Food Intake in Male Rats via the Dorsomedial Hypothalamic Nucleus and not the Paraventricular Hypothalamic Nucleus
Endocrinology, October 1, 2001; 142(10): 4236 - 4243.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
S. J. Getting, G. H. Allcock, R. Flower, and M. Perretti
Natural and synthetic agonists of the melanocortin receptor type 3 possess anti-inflammatory properties
J. Leukoc. Biol., January 1, 2001; 69(1): 98 - 104.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
P. D. Raposinho, E. Castillo, V. D'alleves, P. Broqua, F. P. Pralong, and M. L. Aubert
Chronic Blockade of the Melanocortin 4 Receptor Subtype Leads to Obesity Independently of Neuropeptide Y Action, with No Adverse Effects on the Gonadotropic and Somatotropic Axes
Endocrinology, December 1, 2000; 141(12): 4419 - 4427.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
B. Murphy, C. N. Nunes, J. J. Ronan, M. Hanaway, A. M. Fairhurst, and T. N. Mellin
Centrally administered MTII affects feeding, drinking, temperature, and activity in the Sprague-Dawley rat
J Appl Physiol, July 1, 2000; 89(1): 273 - 282.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
S. P. Kalra, M. G. Dube, S. Pu, B. Xu, T. L. Horvath, and P. S. Kalra
Interacting Appetite-Regulating Pathways in the Hypothalamic Regulation of Body Weight
Endocr. Rev., February 1, 1999; 20(1): 68 - 100.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1998 by The Endocrine Society